Scientists at MIT have developed the first orally administered CRISPR gene therapy that successfully treats genetic disorders of the digestive tract in clinical trials. The breakthrough could revolutionize treatment for conditions like celiac disease and inflammatory bowel disease.
The therapy uses specially engineered lipid nanoparticles that protect the CRISPR components through the acidic stomach environment and deliver them directly to intestinal epithelial cells. Phase 1 trials in celiac disease patients showed that a single course of oral capsules reduced gluten sensitivity by 70%.
Current CRISPR therapies require intravenous infusion in clinical settings, limiting their accessibility and driving costs above $1 million per treatment. An oral formulation could dramatically reduce costs and expand access to gene therapy.
The celiac disease application is particularly significant because it affects an estimated 3 million Americans, many of whom struggle with strict gluten-free diets. A treatment that restores gluten tolerance would transform their quality of life.
Phase 2 trials are planned for late 2026, with potential FDA approval by 2028. Researchers are also exploring oral CRISPR applications for Crohn's disease and hereditary colon cancer syndromes.
